Psoriasis: From Pathogenesis to Pharmacological and Nano-Technological-Based Therapeutics

Robert G. Petit(Universitat de Barcelona), Elena Sánchez‐López(Instituto de Salud Carlos III), Amanda Cano(Biomedical Research Networking Center on Neurodegenerative Diseases), Marta Espina(Institut de Nanociència i Nanotecnologia de la Universitat de Barcelona), A. Ortiz(Institut de Nanociència i Nanotecnologia de la Universitat de Barcelona), Montserrat Pujol(Institut de Nanociència i Nanotecnologia de la Universitat de Barcelona), Eliana B. Souto(Universidade do Porto), Patrícia Severino(Universidade Tiradentes), Montserrat Muñoz-Mateu(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), María L. García(Institut de Nanociència i Nanotecnologia de la Universitat de Barcelona), Josefina Prat(Institut de Nanociència i Nanotecnologia de la Universitat de Barcelona)
International Journal of Molecular Sciences
May 7, 2021
10.3390/ijms22094983
Cited by 150

Related Papers

Metal-Based Nanoparticles as Antimicrobial Agents: An Overview
|Nanomaterials|2020|1.4k
Therapeutic potential of venom peptides
|Nature Reviews Drug Discovery|2003|786
Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery
|International Journal of Pharmaceutics|2004|664
HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial
|The Lancet Oncology|2017|340
Dual-drug loaded nanoparticles of Epigallocatechin-3-gallate (EGCG)/Ascorbic acid enhance therapeutic efficacy of EGCG in a APPswe/PS1dE9 Alzheimer's disease mice model
|Journal of Controlled Release|2019|330